Fibrillar forms of the Amyloid- (A) protein have been implicated in the early stages of Alzheimer's disease (AD), however there are no standardised assays for soluble A oligomer biomarkers that provide the best indication of the disease progression [1,2]. As a step towards a fast and label-free method for testing different AD biomarkers, we have combined laser nano-textured substrates with a SERS mapping technique and validated it using soluble A-40 oligomers [3-5]. The nano-textured SERS substrates provide fast (&5min), label-free spectra associated with soluble A-40 oligomers down to a concentration of 10 nM. Statistical analysis of the spectral intensities mapped over the substrate surface shows a quantitative correlation with t...
Protein misfolded proteins are among the most toxic endogenous species of macromolecules. These chem...
[EN] A central aspect to fully reach the biosensing scope of plasmonics beyond the research environm...
The continuous increasing rate of patients suffering of Alzheimer's disease (AD) worldwide requires ...
Schematics of experiments: SERS mapping of Aβ-40 (left figure: measured SERS intensity overlayed wit...
Abstract Currently, no methods exist for the definitive diagnosis of AD premortem. β-amyloid, the pr...
A nanofluidic biosensor using surface-enhanced Raman scattering (SERS) was developed to detect the β...
Trace detection of the conformational transition of -amyloid peptide (A) from a predominantly r-heli...
Early diagnosis of Alzheimer’s disease (AD) is critical for disease prevention and cure, but no meth...
The growing burden of neurodegenerative diseases on society necessitates the development of improved...
Alzheimer disease (AD) is a major cause of death in the world, and despite intense efforts, there is...
The continuous increasing rate of patients suffering of Alzheimer’s disease (AD) worldwide requires ...
One of the pathological hallmarks of Alzheimer’s disease (AD) is the abnormal aggregation of amyloid...
Amyloid-β protein (Aβ) is a major biomarker candidate for the diagnosis of Alzheimer’s disease (AD)....
The early diagnosis of Alzheimer’s disease (AD) remains a challenge for medical scientists worldwide...
Surface enhanced Raman spectroscopy (SERS) holds great promise in biosensing because of its single-m...
Protein misfolded proteins are among the most toxic endogenous species of macromolecules. These chem...
[EN] A central aspect to fully reach the biosensing scope of plasmonics beyond the research environm...
The continuous increasing rate of patients suffering of Alzheimer's disease (AD) worldwide requires ...
Schematics of experiments: SERS mapping of Aβ-40 (left figure: measured SERS intensity overlayed wit...
Abstract Currently, no methods exist for the definitive diagnosis of AD premortem. β-amyloid, the pr...
A nanofluidic biosensor using surface-enhanced Raman scattering (SERS) was developed to detect the β...
Trace detection of the conformational transition of -amyloid peptide (A) from a predominantly r-heli...
Early diagnosis of Alzheimer’s disease (AD) is critical for disease prevention and cure, but no meth...
The growing burden of neurodegenerative diseases on society necessitates the development of improved...
Alzheimer disease (AD) is a major cause of death in the world, and despite intense efforts, there is...
The continuous increasing rate of patients suffering of Alzheimer’s disease (AD) worldwide requires ...
One of the pathological hallmarks of Alzheimer’s disease (AD) is the abnormal aggregation of amyloid...
Amyloid-β protein (Aβ) is a major biomarker candidate for the diagnosis of Alzheimer’s disease (AD)....
The early diagnosis of Alzheimer’s disease (AD) remains a challenge for medical scientists worldwide...
Surface enhanced Raman spectroscopy (SERS) holds great promise in biosensing because of its single-m...
Protein misfolded proteins are among the most toxic endogenous species of macromolecules. These chem...
[EN] A central aspect to fully reach the biosensing scope of plasmonics beyond the research environm...
The continuous increasing rate of patients suffering of Alzheimer's disease (AD) worldwide requires ...